JP3721077B2 - 性的不全を治療するためのピラゾロピリミジノンcGMPPDE5阻害剤 - Google Patents
性的不全を治療するためのピラゾロピリミジノンcGMPPDE5阻害剤 Download PDFInfo
- Publication number
- JP3721077B2 JP3721077B2 JP2000544672A JP2000544672A JP3721077B2 JP 3721077 B2 JP3721077 B2 JP 3721077B2 JP 2000544672 A JP2000544672 A JP 2000544672A JP 2000544672 A JP2000544672 A JP 2000544672A JP 3721077 B2 JP3721077 B2 JP 3721077B2
- Authority
- JP
- Japan
- Prior art keywords
- title compound
- mmol
- pyridin
- embedded image
- reduced pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CCC(C)COC(CC(*)=CC(S(N1CCN(CC)CC1)(=O)=O)=C1)=C1C(NC(C1=N)=O)=NC1=C(CC)NCC Chemical compound CCC(C)COC(CC(*)=CC(S(N1CCN(CC)CC1)(=O)=O)=C1)=C1C(NC(C1=N)=O)=NC1=C(CC)NCC 0.000 description 1
- XIPXDZHCXFCAGE-UHFFFAOYSA-N CCC(C)Oc(c(C(N1)=Nc2c(CC)[n](CC)nc2C1=O)c1)ncc1S(N1CCN(CC)CC1)(=O)=O Chemical compound CCC(C)Oc(c(C(N1)=Nc2c(CC)[n](CC)nc2C1=O)c1)ncc1S(N1CCN(CC)CC1)(=O)=O XIPXDZHCXFCAGE-UHFFFAOYSA-N 0.000 description 1
- PDCLVOOLDXNNPV-UHFFFAOYSA-N CCc([n](C)nc1C(N)=O)c1NC(c1cc(S(N2CCN(CC)CC2)(=O)=O)cnc1OCC)=O Chemical compound CCc([n](C)nc1C(N)=O)c1NC(c1cc(S(N2CCN(CC)CC2)(=O)=O)cnc1OCC)=O PDCLVOOLDXNNPV-UHFFFAOYSA-N 0.000 description 1
- OUZVHPZKCZEEIJ-UHFFFAOYSA-N CCc([n](CC)nc12)c1N=C(c1cc(S(N3CCN(CC)CC3)(=O)=O)cnc1OCCOC)NC2=O Chemical compound CCc([n](CC)nc12)c1N=C(c1cc(S(N3CCN(CC)CC3)(=O)=O)cnc1OCCOC)NC2=O OUZVHPZKCZEEIJ-UHFFFAOYSA-N 0.000 description 1
- XHWDFGQAXHSIMH-UHFFFAOYSA-N COc1cccc(CBr)n1 Chemical compound COc1cccc(CBr)n1 XHWDFGQAXHSIMH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9808315.7 | 1998-04-20 | ||
GBGB9808315.7A GB9808315D0 (en) | 1998-04-20 | 1998-04-20 | Therapeutic agents |
GB9814187.2 | 1998-06-30 | ||
GBGB9814187.2A GB9814187D0 (en) | 1998-06-30 | 1998-06-30 | Therapeutic agents |
PCT/IB1999/000519 WO1999054333A1 (en) | 1998-04-20 | 1999-03-25 | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003390698A Division JP2004099620A (ja) | 1998-04-20 | 2003-11-20 | ピラゾロピリミジノンcGMPPDE5阻害剤の製造における合成中間体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002512248A JP2002512248A (ja) | 2002-04-23 |
JP3721077B2 true JP3721077B2 (ja) | 2005-11-30 |
Family
ID=26313490
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000544672A Expired - Fee Related JP3721077B2 (ja) | 1998-04-20 | 1999-03-25 | 性的不全を治療するためのピラゾロピリミジノンcGMPPDE5阻害剤 |
JP2003390698A Withdrawn JP2004099620A (ja) | 1998-04-20 | 2003-11-20 | ピラゾロピリミジノンcGMPPDE5阻害剤の製造における合成中間体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003390698A Withdrawn JP2004099620A (ja) | 1998-04-20 | 2003-11-20 | ピラゾロピリミジノンcGMPPDE5阻害剤の製造における合成中間体 |
Country Status (40)
Country | Link |
---|---|
US (2) | US6251904B1 (es) |
EP (2) | EP1073658B1 (es) |
JP (2) | JP3721077B2 (es) |
KR (1) | KR100449790B1 (es) |
CN (2) | CN1229349C (es) |
AP (1) | AP1022A (es) |
AR (2) | AR015770A1 (es) |
AT (2) | ATE299503T1 (es) |
AU (1) | AU748352B2 (es) |
BG (1) | BG104949A (es) |
BR (1) | BR9909808A (es) |
CA (1) | CA2329077C (es) |
CO (1) | CO5271649A1 (es) |
DE (2) | DE69910368T2 (es) |
DK (2) | DK1073658T3 (es) |
DZ (1) | DZ2773A1 (es) |
EA (1) | EA200000969A1 (es) |
ES (2) | ES2242124T3 (es) |
GT (1) | GT199900053A (es) |
HK (1) | HK1064670A1 (es) |
HR (1) | HRP20000712A2 (es) |
HU (1) | HUP0102543A3 (es) |
ID (1) | ID27036A (es) |
IL (2) | IL138907A0 (es) |
IS (1) | IS5650A (es) |
MA (1) | MA26622A1 (es) |
NO (1) | NO20005255L (es) |
OA (1) | OA11502A (es) |
PA (1) | PA8470501A1 (es) |
PE (1) | PE20000463A1 (es) |
PL (1) | PL343794A1 (es) |
PT (2) | PT1073658E (es) |
RS (1) | RS50011B (es) |
SI (2) | SI1371647T1 (es) |
SK (1) | SK15532000A3 (es) |
TN (1) | TNSN99073A1 (es) |
TR (1) | TR200003039T2 (es) |
TW (1) | TW593310B (es) |
UY (1) | UY25484A1 (es) |
WO (1) | WO1999054333A1 (es) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL336586A1 (en) | 1997-04-25 | 2000-07-03 | Pfizer | Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
HUP0102543A3 (en) * | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
GB9823102D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
US6242444B1 (en) | 1999-06-04 | 2001-06-05 | The Jordanian Pharmaceutical Manufacturing And Medical Equipment Co., Ltd. | Compounds and pharmaceutical compositions containing the same |
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
US6350751B1 (en) * | 1999-10-11 | 2002-02-26 | Pfizer Inc. | Therapeutic agents |
GB9924020D0 (en) | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Pharmaceutically active compounds |
TWI265925B (en) * | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
YU59100A (sh) * | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
GB9923968D0 (en) * | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Therapeutic agents |
EP1222190A1 (en) * | 1999-10-11 | 2002-07-17 | Pfizer Limited | 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
IL139073A0 (en) * | 1999-10-21 | 2001-11-25 | Pfizer | Treatment of neuropathy |
TW200400821A (en) * | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
JP2004500425A (ja) * | 2000-04-19 | 2004-01-08 | リリー アイコス リミテッド ライアビリティ カンパニー | パーキンソン病の処置に対する環状gmp特異的ホスホジエステラーゼインヒビターの使用 |
US6667398B2 (en) * | 2000-06-22 | 2003-12-23 | Pfizer Inc | Process for the preparation of pyrazolopyrimidinones |
US6730786B2 (en) | 2000-06-22 | 2004-05-04 | Pfizer Inc | Process for the preparation of pyrazolopyrimidinones |
US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6420557B1 (en) * | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
EE200300045A (et) * | 2000-07-28 | 2004-12-15 | Pfizer Inc. | Kristalne ravimaine |
US6809200B2 (en) * | 2000-07-28 | 2004-10-26 | Pfizer Inc. | Process for the preparation of pyrazolo[4,3-d]pyrimidin-7-one compounds and intermediates thereof |
US6821978B2 (en) | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
GB0105893D0 (en) * | 2001-03-09 | 2001-04-25 | Pfizer Ltd | Pharmaceutically active compounds |
US6831074B2 (en) * | 2001-03-16 | 2004-12-14 | Pfizer Inc | Pharmaceutically active compounds |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
EP1442042A1 (en) | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
DK1348707T3 (da) * | 2002-03-28 | 2010-12-13 | Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro | Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
ES2341240T3 (es) | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
WO2004096810A1 (en) | 2003-04-29 | 2004-11-11 | Pfizer Limited | 5,7-diaminopyrazolo`4,3-d!pyrimidines useful in the treatment of hypertension |
CN100374441C (zh) * | 2003-06-06 | 2008-03-12 | 天津倍方科技发展有限公司 | 二氢吡咯[2,3-d]嘧啶-4-酮衍生物,其制备方法及其制药用途 |
US20050079548A1 (en) * | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
EP1708718A1 (en) | 2004-01-22 | 2006-10-11 | Pfizer Limited | Triazole derivatives which inhibit vasopressin antagonistic activity |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
WO2005097799A1 (en) | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3-d! pyrimidines |
CA2577442A1 (en) * | 2004-08-17 | 2006-03-02 | The Johns Hopkins University | Pde5 inhibitor compositions and methods for treating cardiac indications |
ATE412648T1 (de) | 2005-03-21 | 2008-11-15 | Pfizer Ltd | Substituierte triazolderivate als oxytocinantagonisten |
US20060235028A1 (en) * | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
ES2433661T3 (es) | 2005-04-19 | 2013-12-12 | Takeda Gmbh | Roflumilast para el tratamiento de hipertensión pulmonar |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス,インコーポレイティド | ムスカリン性受容体調節による神経発生 |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008070095A1 (en) * | 2006-12-05 | 2008-06-12 | Intra-Cellular Therapies, Inc. | Novel uses |
KR100989093B1 (ko) | 2008-01-18 | 2010-10-25 | 한화제약주식회사 | 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물 |
CN101747282A (zh) | 2008-12-10 | 2010-06-23 | 上海特化医药科技有限公司 | 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途 |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
MX2010006227A (es) | 2010-06-07 | 2011-12-14 | World Trade Imp Exp Wtie Ag | Nuevos derivados 1,4-diazepanos, inhibidores de pde-5. |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
US10899756B2 (en) | 2013-07-17 | 2021-01-26 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
EP3099689B1 (en) | 2014-01-30 | 2022-01-26 | Council of Scientific and Industrial Research | Pyrazolopyrimidinones for the treatment of impotence and process for the preparation thereof |
CN103922960B (zh) * | 2014-04-16 | 2015-10-21 | 浙江中山化工集团股份有限公司 | 一种s-异丙甲草胺的合成方法 |
CN104402811A (zh) * | 2014-11-11 | 2015-03-11 | 常州大学 | 一种合成二甲氨基吡啶甲酸的方法 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
KR102507967B1 (ko) | 2016-09-09 | 2023-03-09 | 인사이트 코포레이션 | Hpk1 조절제로서의 피라졸로피리딘 유도체 및 암을 치료하기 위한 이의 용도 |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
CN112313224A (zh) * | 2018-04-06 | 2021-02-02 | 黑带医疗有限责任公司 | Atf6抑制剂和其用途 |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
CN114450276A (zh) | 2019-08-06 | 2022-05-06 | 因赛特公司 | Hpk1抑制剂的固体形式 |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871843A (en) | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
US4663326A (en) | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
US5734053A (en) | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
HUP9801394A3 (en) | 1995-03-10 | 2000-07-28 | Sanofi Pharmaceuticals Inc New | 6-phenyl-pyrazolo[3,4-d]pyrimidin-4-one derivatives and pharmaceutical compositions containing them |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
PL336586A1 (en) * | 1997-04-25 | 2000-07-03 | Pfizer | Pyrazoylpyrimidinones inhibiting the cyclic guanosine 3',5'-monophosphate phosphodiesterase of type 5 (cgmp pde5) for treating sexual disorders |
HUP0102543A3 (en) | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
-
1999
- 1999-03-25 HU HU0102543A patent/HUP0102543A3/hu unknown
- 1999-03-25 DE DE69910368T patent/DE69910368T2/de not_active Expired - Fee Related
- 1999-03-25 AT AT03013988T patent/ATE299503T1/de not_active IP Right Cessation
- 1999-03-25 SI SI9930802T patent/SI1371647T1/xx unknown
- 1999-03-25 ES ES03013988T patent/ES2242124T3/es not_active Expired - Lifetime
- 1999-03-25 DK DK99907805T patent/DK1073658T3/da active
- 1999-03-25 IL IL13890799A patent/IL138907A0/xx not_active IP Right Cessation
- 1999-03-25 PL PL99343794A patent/PL343794A1/xx not_active IP Right Cessation
- 1999-03-25 CA CA002329077A patent/CA2329077C/en not_active Expired - Fee Related
- 1999-03-25 TR TR2000/03039T patent/TR200003039T2/xx unknown
- 1999-03-25 CN CNB031579582A patent/CN1229349C/zh not_active Expired - Fee Related
- 1999-03-25 PT PT99907805T patent/PT1073658E/pt unknown
- 1999-03-25 RS YUP-635/00A patent/RS50011B/sr unknown
- 1999-03-25 EP EP99907805A patent/EP1073658B1/en not_active Expired - Lifetime
- 1999-03-25 BR BR9909808-3A patent/BR9909808A/pt not_active Application Discontinuation
- 1999-03-25 EP EP03013988A patent/EP1371647B1/en not_active Expired - Lifetime
- 1999-03-25 ES ES99907805T patent/ES2203078T3/es not_active Expired - Lifetime
- 1999-03-25 WO PCT/IB1999/000519 patent/WO1999054333A1/en active IP Right Grant
- 1999-03-25 SI SI9930361T patent/SI1073658T1/xx unknown
- 1999-03-25 KR KR10-2000-7011569A patent/KR100449790B1/ko not_active IP Right Cessation
- 1999-03-25 PT PT03013988T patent/PT1371647E/pt unknown
- 1999-03-25 EA EA200000969A patent/EA200000969A1/ru unknown
- 1999-03-25 AU AU27425/99A patent/AU748352B2/en not_active Ceased
- 1999-03-25 CN CNB998072885A patent/CN1134442C/zh not_active Expired - Fee Related
- 1999-03-25 ID IDW20002117A patent/ID27036A/id unknown
- 1999-03-25 JP JP2000544672A patent/JP3721077B2/ja not_active Expired - Fee Related
- 1999-03-25 DK DK03013988T patent/DK1371647T3/da active
- 1999-03-25 AT AT99907805T patent/ATE247117T1/de not_active IP Right Cessation
- 1999-03-25 US US09/402,242 patent/US6251904B1/en not_active Expired - Fee Related
- 1999-03-25 DE DE69926154T patent/DE69926154T2/de not_active Expired - Fee Related
- 1999-03-25 SK SK1553-2000A patent/SK15532000A3/sk unknown
- 1999-03-26 TW TW088104856A patent/TW593310B/zh not_active IP Right Cessation
- 1999-04-07 PA PA19998470501A patent/PA8470501A1/es unknown
- 1999-04-13 GT GT199900053A patent/GT199900053A/es unknown
- 1999-04-15 AP APAP/P/1999/001514A patent/AP1022A/en active
- 1999-04-16 CO CO99022946A patent/CO5271649A1/es not_active Application Discontinuation
- 1999-04-16 AR ARP990101780A patent/AR015770A1/es active IP Right Grant
- 1999-04-16 PE PE1999000322A patent/PE20000463A1/es not_active Application Discontinuation
- 1999-04-19 TN TNTNSN99073A patent/TNSN99073A1/fr unknown
- 1999-04-19 DZ DZ990073A patent/DZ2773A1/xx active
- 1999-04-19 MA MA25542A patent/MA26622A1/fr unknown
- 1999-04-20 UY UY25484A patent/UY25484A1/es not_active Application Discontinuation
-
2000
- 2000-09-29 IS IS5650A patent/IS5650A/is unknown
- 2000-10-05 IL IL138907A patent/IL138907A/en unknown
- 2000-10-13 OA OA1200000284A patent/OA11502A/en unknown
- 2000-10-19 NO NO20005255A patent/NO20005255L/no not_active Application Discontinuation
- 2000-10-20 HR HR20000712A patent/HRP20000712A2/hr not_active Application Discontinuation
- 2000-11-15 BG BG104949A patent/BG104949A/xx unknown
-
2001
- 2001-04-30 US US09/845,420 patent/US6458951B2/en not_active Expired - Fee Related
- 2001-11-12 HK HK04107545A patent/HK1064670A1/xx not_active IP Right Cessation
-
2003
- 2003-11-20 JP JP2003390698A patent/JP2004099620A/ja not_active Withdrawn
-
2006
- 2006-11-24 AR ARP060105188A patent/AR057934A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3721077B2 (ja) | 性的不全を治療するためのピラゾロピリミジノンcGMPPDE5阻害剤 | |
JP4036836B2 (ja) | 性的機能障害治療用の5型サイクリックグアノシン3′,5′−一リン酸ホスホジエステラーゼ(cGMPPDE5)を阻害するピラゾロピリミジノン類中間体の製造方法 | |
JP3834236B2 (ja) | ピラゾロ〔4,3−d〕ピリミジン誘導体 | |
DE69925970T2 (de) | Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion | |
JP2000128883A (ja) | 性的機能障害の治療用のピラゾロピリミジノンcGMPPDE5阻害剤 | |
JP2002528456A (ja) | 性的機能障害の処置のためのピラゾロピリミジノン系cGMP阻害薬 | |
KR20020038941A (ko) | 포스포디에스테라아제 억제제로서의5-(2-치환된-5-헤테로사이클릴설포닐피리드-3-일)-디하이드로피라졸로[4,3-d]피리미딘-7-온 | |
JP2004523585A (ja) | サイクリックグアノシン3’,5’−モノホスフェートホスホジエステラーゼ阻害剤 | |
CA2585557C (en) | Pyrazolo[4,3-d] pyrimidine derivatives useful as pde-5 inhibitors | |
MXPA00010388A (es) | Pirazolopirimidinonas inhibidoras de gmpc pde5 para el tratamiento de la disfuncion sexual | |
CZ20003882A3 (cs) | Pyrazolpyrimidinové inhibitory CGMP PDE5 pro léčbu sexuálních dysfunkcí |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040206 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040426 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050819 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050909 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080916 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090916 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |